In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...
Company to host corporate update call on Tuesday, March 17, at 4 p.m. ETSAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, ...
Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...
AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral ...
In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...
Arteries are blood vessels that carry blood away from your heart. Pulmonary arterial hypertension (PAH) is a condition where you have high blood pressure in the arteries that go from your heart to ...
A new study has found that asporin, a protein encoded by the ASPN gene, plays a protective role in pulmonary arterial hypertension (PAH). A new study from researchers with UCLA Health and ...
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...
In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this report, we follow up on what has happened since. After the FDA approved both ...
Positive airway pressure therapy is linked with reduced pulmonary arterial pressures in patients with severe obstructive sleep apnea or obesity hypoventilation syndrome.
New findings reveal pulmonary arterial hypertension may affect the brain early. Learn how inflammation and cognitive decline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results